Hanmi, Beijing Hanmi & Innovent signs co-development partnership of immuno-oncology bispecific antibody

Published: 2017-04-03 14:45:46

Updated: 2017-04-03 14:45:46

Hanmi Pharm(CEO Sae-Chang Kwon, Jong-Soo Woo) announced on the 30^th that it has established a global partnership to jointly develop and commercialize a immune-oncology bispecific antibody with the Chinese biotechnology company Innovent Biologics Co. Ltd.

The bispecific antibody that is jointly being developed by the two companies enables immunotherapy and targeted therapy at the same time. It ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.